Back to pipeline

First-in-class therapeutic mechanism for Diastolic Heart Failure treatment

VASA Therapeutics 1

Therapeutic area
Cardiovascular
Location
Poland / USA
Current phase
Advanced Pre-Clinical
Exit
2024
IP
Composition of matter filling Q4 2021

Heart failure is the leading cause of hospitalization for those >65 years and the mortality is >50% within 5 years after first hospital admission. These patients' expenses amount to 2–3% of the total United States healthcare spending. The total US market for heart failure treatments is worth >40 bln USD. Vasa Therapeutics is striving to discover novel heart failure medicines using mechanisms that directly improve heart function and employing precision medicine-based patient stratification. 

 

The target patients for Vasa 1 program are Heart Failure with Preserved Ejection Fraction (HFpEF) patients after first hospitalization for which there currrently is no standard of care. The program looks into MMPs, which are biomarkers and targets of HFpEF. Vasa has developed a proprietary scaffold identified internally and filled a composition of matter filling in Q4 2021.

 

Back to pipeline

Undisclosed I

Next project
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram